Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Johnson and Johnson
Mallinckrodt
Merck
Medtronic

Last Updated: January 27, 2022

DrugPatentWatch Database Preview

Ucb Inc Company Profile


Email this page to a colleague

« Back to Dashboard

Summary for Ucb Inc
International Patents:339
US Patents:18
Tradenames:27
Ingredients:22
NDAs:40
Drug Master File Entries: 1

Drugs and US Patents for Ucb Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-005 Apr 2, 2012 RX Yes No 8,617,591 ⤷  Try it Free Y ⤷  Try it Free
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-005 May 12, 2016 RX Yes Yes 6,784,197 ⤷  Try it Free Y Y ⤷  Try it Free
Ucb Inc BRIVIACT brivaracetam SOLUTION;INTRAVENOUS 205837-001 May 12, 2016 RX Yes Yes 6,911,461 ⤷  Try it Free Y Y ⤷  Try it Free
Ucb Inc NIRAVAM alprazolam TABLET, ORALLY DISINTEGRATING;ORAL 021726-004 Jan 19, 2005 DISCN Yes No ⤷  Try it Free ⤷  Try it Free
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-001 May 12, 2016 RX Yes No ⤷  Try it Free ⤷  Try it Free
Ucb Inc AMITRIPTYLINE HYDROCHLORIDE amitriptyline hydrochloride TABLET;ORAL 085935-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try it Free ⤷  Try it Free
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-006 Apr 2, 2012 RX Yes No 8,246,979 ⤷  Try it Free Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Ucb Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ucb Inc KEMSTRO baclofen TABLET, ORALLY DISINTEGRATING;ORAL 021589-001 Oct 30, 2003 6,024,981 ⤷  Try it Free
Ucb Inc KEPPRA levetiracetam SOLUTION;ORAL 021505-001 Jul 15, 2003 4,837,223 ⤷  Try it Free
Ucb Inc UNIVASC moexipril hydrochloride TABLET;ORAL 020312-002 Apr 19, 1995 4,344,949 ⤷  Try it Free
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-001 May 12, 2016 8,492,416 ⤷  Try it Free
Ucb Inc KEPPRA levetiracetam TABLET;ORAL 021035-003 Nov 30, 1999 4,837,223 ⤷  Try it Free
Ucb Inc FLUXID famotidine TABLET, ORALLY DISINTEGRATING;ORAL 021712-001 Sep 24, 2004 6,221,392 ⤷  Try it Free
Ucb Inc BRIVIACT brivaracetam SOLUTION;ORAL 205838-001 May 12, 2016 8,492,416 ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for UCB INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 1000 mg ➤ Subscribe 2007-01-24
➤ Subscribe Tablets 50 mg, 100 mg, 150 mg, and 200 mg ➤ Subscribe 2012-10-29
➤ Subscribe Extended-release Tablets 1000 mg ➤ Subscribe 2011-01-07
➤ Subscribe Tablets 7.5mg/12.5mg 15 mg/25 mg and 15 mg/12.5 mg ➤ Subscribe 2004-01-15
➤ Subscribe Extended-release Transdermal Film 1 mg/24 hr, 2 mg/24 hr, 3 mg/24 hr,4 mg/24 hr,6 mg/24 hr, and 8 mg/24 hr ➤ Subscribe 2013-11-26
➤ Subscribe Oral Solution 10 mg/mL ➤ Subscribe 2012-10-29
➤ Subscribe Injection 10 mg/mL, 20 mL ➤ Subscribe 2016-06-30
➤ Subscribe Orally Disintegrating Tablets 0.25 mg, 0.5 mg, 1 mg and 2 mg ➤ Subscribe 2005-12-27

Supplementary Protection Certificates for Ucb Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1429780 13C0012 France ⤷  Try it Free PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808
1429780 SPC/GB12/058 United Kingdom ⤷  Try it Free PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
1033978 06C0025 France ⤷  Try it Free PRODUCT NAME: ROTIGOTINE; REGISTRATION NO/DATE: EU/1/05/331/001 20060215
1452524 C01452524/01 Switzerland ⤷  Try it Free PRODUCT NAME: BRIVARACETAM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65830 06.10.2016
0454511 99C0009 Belgium ⤷  Try it Free PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
0503785 CA 2011 00026 Denmark ⤷  Try it Free PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
0162036 C300028 Netherlands ⤷  Try it Free PRODUCT NAME: LEVETIRACETAM; REGISTRATION NO/DATE: EU/1/00/146/001 - EU/1/00/146/026 20000929
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Express Scripts
AstraZeneca
McKesson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.